208 related articles for article (PubMed ID: 9879412)
1. Suplatast tosilate affects the initial increase in specific IgE and interleukin-4 during immunotherapy for perennial allergic rhinitis.
Washio Y; Ohashi Y; Tanaka A; Kakinoki Y; Sugiura Y; Sakamoto H; Yamada K; Matsuda M; Uekawa M; Okamoto H; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():126-32. PubMed ID: 9879412
[TBL] [Abstract][Full Text] [Related]
2. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate.
Kimata H
Ann Allergy Asthma Immunol; 1999 Mar; 82(3):293-5. PubMed ID: 10094221
[TBL] [Abstract][Full Text] [Related]
3. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies.
Furukido K; Takeno S; Ueda T; Hirakawa K; Yajin K
Am J Rhinol; 2002; 16(6):329-36. PubMed ID: 12512908
[TBL] [Abstract][Full Text] [Related]
4. [The effect of suplatast tosilate on immunological parameters for the patients with atopic dermatitis].
Suto H; Mitsuishi K; Hira K; Uchida T; Unno T; Ogawa H; Yoshiike T; Takamori K
Arerugi; 2000 Dec; 49(12):1163-72. PubMed ID: 11197882
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of suplatast tosilate, a Th2 cytokine inhibitor based on the Th1/Th2 ratio for allergic disease in children: a retrospective study.
Yoshihara S; Fukuda H; Arisaka O
Arzneimittelforschung; 2011; 61(7):421-4. PubMed ID: 21899211
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory effects of suplatast tosilate on the differentiation and function of monocyte-derived dendritic cells from patients with asthma.
Tanaka A; Minoguchi K; Samson KT; Oda N; Yokoe T; Tazaki T; Yamamoto Y; Yamamoto M; Ohta S; Adachi M
Clin Exp Allergy; 2007 Jul; 37(7):1083-9. PubMed ID: 17581203
[TBL] [Abstract][Full Text] [Related]
7. [The effect of suplatast tosilate on the patients with atopic dermatitis--relationship between clinical symptoms and immunological parameters].
Higashi N; Niimi Y; Aoki M; Fujimoto K; Suzuki K; Numano K; Kawana S
Arerugi; 2003 Nov; 52(11):1065-73. PubMed ID: 14685038
[TBL] [Abstract][Full Text] [Related]
8. [Chronic eosinophilic pneumonia successfully treated with suplatast tosilate].
Hamada H; Sakatani M; Nishioka M; Akira M; Yamamoto S; Ueda E; Okano Y; Nakamura Y; Sone S
Nihon Kyobu Shikkan Gakkai Zasshi; 1997 Jun; 35(6):692-7. PubMed ID: 9294307
[TBL] [Abstract][Full Text] [Related]
9. Effect of suplatast tosilate on goblet cell metaplasia in patients with asthma.
Hoshino M; Fujita Y; Saji J; Inoue T; Nakagawa T; Miyazawa T
Allergy; 2005 Nov; 60(11):1394-400. PubMed ID: 16197471
[TBL] [Abstract][Full Text] [Related]
10. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5.
Murakami T; Yamanaka K; Tokime K; Kurokawa I; Tsutsui H; Nakanishi K; Mizutani H
Br J Dermatol; 2006 Jul; 155(1):27-32. PubMed ID: 16792748
[TBL] [Abstract][Full Text] [Related]
11. Suplatast tosilate alters DC1/DC2 balance in peripheral blood in bronchial asthma.
Yokomura K; Suda T; Matsuda H; Hashizume H; Asada K; Suzuki K; Chida K
J Asthma; 2005 Sep; 42(7):567-70. PubMed ID: 16169790
[TBL] [Abstract][Full Text] [Related]
12. Suplatast tosilate inhibits goblet-cell metaplasia of airway epithelium in sensitized mice.
Shim JJ; Dabbagh K; Takeyama K; Burgel PR; Dao-Pick TP; Ueki IF; Nadel JA
J Allergy Clin Immunol; 2000 Apr; 105(4):739-45. PubMed ID: 10756224
[TBL] [Abstract][Full Text] [Related]
13. [Cytokine production by peripheral blood mononuclear cells in bronchial asthma treated with suplatast tosilate].
Yamasawa H; Oshikawa K; Sugiyama Y
Arerugi; 2001 Jun; 50(6):513-9. PubMed ID: 11517513
[TBL] [Abstract][Full Text] [Related]
14. CD28 and secretory immunoglobulin A-dependent activation of eosinophils: inhibition of mediator release by the anti-allergic drug, suplatast tosilate.
Woerly G; Decot V; Loiseau S; Loyens M; Chihara J; Ono N; Capron M
Clin Exp Allergy; 2004 Sep; 34(9):1379-87. PubMed ID: 15347370
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis.
Nagakura T; Ogino S; Okubo K; Sato N; Takahashi M; Ishikawa T
Clin Exp Allergy; 2008 Feb; 38(2):329-37. PubMed ID: 18070163
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the clinical efficacy of immunotherapy and conventional pharmacological treatment for patients with perennial allergic rhinitis.
Ohashi Y; Nakai Y; Tanaka A; Kakinoki Y; Washio Y; Yamada K; Sakamoto H; Nasako Y; Hayashi M; Nakai Y
Acta Otolaryngol Suppl; 1998; 538():102-12. PubMed ID: 9879409
[TBL] [Abstract][Full Text] [Related]
17. Effect of an orally active Th2 cytokine inhibitor, suplatast on "atopic cough" tosilate.
Ishiura Y; Fujimura M; Yamamoto H; Nobata K; Ishiguro T; Ogawa H; Myou S
Arzneimittelforschung; 2008; 58(6):297-302. PubMed ID: 18677972
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitory effect of suplatast tosilate on eosinophil migration].
Kobayashi Y; Nagata M; Yamamoto H; Sakamoto Y
Arerugi; 2000 Jul; 49(7):600-3. PubMed ID: 10944827
[TBL] [Abstract][Full Text] [Related]
19. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10-production.
Cosmi L; Santarlasci V; Angeli R; Liotta F; Maggi L; Frosali F; Rossi O; Falagiani P; Riva G; Romagnani S; Annunziato F; Maggi E
Clin Exp Allergy; 2006 Mar; 36(3):261-72. PubMed ID: 16499636
[TBL] [Abstract][Full Text] [Related]
20. Suplatast tosilate inhibits thymus- and activation-regulated chemokine production by antigen-specific human Th2 cells.
Oda N; Minoguchi K; Tanaka A; Yokoe T; Minoguchi H; Matsuo H; Nakashima M; Tasaki T; Adachi M
Clin Exp Allergy; 2002 Dec; 32(12):1782-6. PubMed ID: 12653172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
